Previous Close | 1.2900 |
Open | 1.2900 |
Bid | 1.3300 x 1300 |
Ask | 1.3500 x 1100 |
Day's Range | 1.2900 - 1.4000 |
52 Week Range | 0.3820 - 2.1700 |
Volume | |
Avg. Volume | 958,364 |
Market Cap | 104.008M |
Beta (5Y Monthly) | -1.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2490 |
Earnings Date | Aug 15, 2022 - Aug 22, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.17 |
Subscribe to Yahoo Finance Plus to view Fair Value for VTVT
A look at the shareholders of vTv Therapeutics Inc. ( NASDAQ:VTVT ) can tell us which group is most powerful. Large...
A Cincinnati-based portfolio company that celebrated a massive exit earlier this year has invested millions to accelerate development of a new treatment option for people with Type 1 diabetes.
Following several leadership changes, High Point clinical stage pharmaceutical company vTv therapeutics Inc. has named Paul Sekhri as president and chief executive officer. He joins the company as it prepares to enter Phase 3 trials for its orally delivered Type 1 Diabetes treatment.